Biodesix (BDSX) AI Stock Analysis

• Market Cap: $163.55M
• Dividend Yield: N/A
• Average Volume (3M): 107.55K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.45
• Revenue Growth: 22.29%
• EPS Growth: 31.93%
• Country: US
• Employees: 273
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.49
• Shares Outstanding: 9,858,358
• 10 Day Avg. Volume: 48,205
• 30 Day Avg. Volume: 107,552
• PEG Ratio: 0.05
• Price to Book (P/B): -20.83
• Price to Sales (P/S): 0.58
• P/FCF Ratio: -2.18
• Enterprise Value/Market Cap: 1.09
• Enterprise Value/Revenue: 2.01
• Enterprise Value/Gross Profit: 2.48
• Enterprise Value/Ebitda: -8.11
• 1Y Price Target: $30.00
• Price Target Upside: 80.83% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -3.16
• Revenue Forecast (FY): $108.68M

• Rating: 56 Neutral
• Price Target: $18.50 ▲(11.51% Upside)
• Action: Reiterated Date: 02/27/26
• Date: Action: Reiterated 02/27/26

The score is held back primarily by weak financial performance (ongoing losses, cash burn, and a stressed balance sheet with negative equity). Offsetting this are constructive earnings-call signals (strong 2026 growth guidance, high gross margins, and momentum toward adjusted EBITDA positivity) and a favorable technical trend, though overbought indicators add near-term risk.

Positive Factors

Revenue Growth & 2026 Guidance

Biodesix has moved from low-to-mid single-digit growth to sustained acceleration: 2025 revenue grew ~24% and management guided ~23% growth for 2026. This suggests durable commercial traction in lung diagnostics and a multi-quarter revenue runway driven by volume, ASP gains, and expanded sales coverage.

High Gross Margins

Persistently ~80% gross margins indicate advantaged unit economics for Biodesix's proteomic tests. High margins improve operating leverage as volumes scale, enabling faster conversion of revenue growth into sustainable profitability if commercial momentum and payer coverage persist.

Commercial Expansion & Strategic Partnerships

Scaling the salesforce and adding reps quarter-over-quarter is a structural driver of durable test adoption and ASP improvement. Coupled with partnerships (e.g., Thermo Fisher, Bio‑Rad) and pipeline work, the commercial buildout supports repeatable volume growth and biopharma services revenue diversification over the medium term.

Negative Factors

Stressed Balance Sheet & Leverage

Negative equity and nearly $73M of debt materially weaken financial flexibility. High leverage raises refinancing and covenant risk, limits ability to absorb shocks or invest opportunistically, and increases dependence on external capital during scale-up until consistent profits and cash generation appear.

Persistent Cash Burn

Despite improvement, operating and free cash flow remain negative and cash burn persists, requiring recurring financing to fund growth. Continued reliance on equity raises and loan amendments exposes operations to market conditions and could force trade-offs between growth investments and near-term liquidity preservation.

Delayed Clinical Catalyst & Reimbursement Uncertainty

The ALTITUDE trial delay pushes a key clinical readout beyond the near term, deferring a major evidence catalyst that could influence guideline adoption and payer decisions. Combined with unspecified timing of HEDIS/guideline updates, this lengthens commercialization timelines and heightens reimbursement risk for new indications.

Biodesix Business Overview & Revenue Model

Company Description

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.

How the Company Makes Money

Biodesix makes money primarily through (1) clinical testing revenue and (2) biopharma services revenue. 1) Clinical testing (diagnostic testing for patients): Biodesix generates revenue when its laboratory performs and reports results for its proprietary diagnostic tests ordered by healthcare providers. Payment is received from third-party payers (such as commercial insurers and government programs) or, in some cases, directly from patients/clients depending on coverage and billing arrangements. Revenue is driven by test volume, realized reimbursement per test, and the breadth of payer coverage and contracted rates. 2) Biopharma services (partnership and development work): Biodesix also earns revenue by providing services to biopharmaceutical companies, which can include work related to developing, validating, and using diagnostic approaches in drug development and clinical trials (e.g., supporting patient stratification or treatment-response assessment in precision medicine programs). This revenue typically comes from contracted service fees and may depend on the scope and timing of partner projects. Key factors affecting earnings include: (a) physician adoption and utilization of its tests, (b) payer coverage decisions and reimbursement levels, (c) the company’s ability to maintain and expand contracts with biopharma partners, and (d) operational execution in running its laboratory testing and delivering clinically actionable reports. Specific test names, detailed payer mix, exact reimbursement rates, and named partnerships are null because they are not provided in the prompt and cannot be confirmed here without referencing current filings or other source documents.

Biodesix Financial Statement Overview

Summary

Revenue growth is improving, but the overall financial profile remains high-risk: the company is still deeply loss-making, free cash flow is negative, and the balance sheet weakened with stockholders’ equity turning negative alongside sizable debt—limiting financial flexibility.

Income Statement

Revenue growth has improved meaningfully, accelerating to ~10.4% in 2025 versus low-to-mid single digit growth in prior years, showing better commercial traction. However, profitability remains weak: the company is still deeply loss-making with a ~-39.8% net margin in 2025 and negative EBITDA margins across all periods provided. While losses have narrowed versus 2022–2024, the business has not yet demonstrated a path to sustained operating profitability in the reported results.

Balance Sheet

Leverage has risen and the balance sheet weakened materially in 2025 as stockholders’ equity turned negative (-$2.5M) alongside ~$72.9M of total debt, which is a key risk signal and reduces financial flexibility. Prior years show equity was positive but declining and debt-to-equity moved sharply higher over time (from ~0.5x in 2021 to ~13.3x in 2023 before equity flipped negative). Overall, the capital structure appears stressed for a diagnostics company still generating net losses.

Cash Flow

Cash generation remains a major concern: operating cash flow and free cash flow are negative in every year shown, including 2025 (operating cash flow -$23.3M; free cash flow -$23.5M). The burn rate improved substantially from 2024 (operating cash flow -$48.6M; free cash flow -$51.9M), but free cash flow still deteriorated versus 2024 on a growth basis (about -19.6%). Overall, the company is relying on external funding to support operations until cash flows turn sustainably positive.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	88.50M	71.32M	49.09M	38.21M	54.51M
Gross Profit	66.59M	55.75M	36.08M	24.06M	23.99M
EBITDA	-21.88M	-29.22M	-37.10M	-51.53M	-35.47M
Net Income	-35.27M	-42.93M	-52.15M	-65.45M	-43.16M
Balance Sheet
Total Assets	87.48M	97.24M	99.10M	92.91M	76.10M
Cash, Cash Equivalents and Short-Term Investments	18.99M	26.25M	26.28M	43.09M	32.71M
Total Debt	72.85M	61.98M	60.69M	31.85M	10.01M
Total Liabilities	89.94M	76.37M	94.52M	72.30M	56.37M
Stockholders Equity	-2.46M	20.88M	4.58M	20.61M	19.73M
Cash Flow
Free Cash Flow	-23.53M	-51.88M	-45.93M	-48.51M	-30.77M
Operating Cash Flow	-23.27M	-48.65M	-22.87M	-44.97M	-28.22M
Investing Cash Flow	-403.00K	-3.44M	-23.06M	-3.53M	-2.55M
Financing Cash Flow	16.42M	52.05M	29.13M	58.88M	1.26M

Biodesix Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 16.59
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDSX, the sentiment is Positive. The current price of 16.59 is above the 20-day moving average (MA) of 15.80, above the 50-day MA of 12.00, and above the 200-day MA of 8.45, indicating a bullish trend. The MACD of 1.83 indicates Positive momentum. The RSI at 58.55 is Neutral, neither overbought nor oversold. The STOCH value of 47.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BDSX.

Biodesix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BNR	57 Neutral	$199.72M	-2.82	-21.40%	―	5.44%	72.17%
BDSX	56 Neutral	$163.55M	-1.46	-302.55%	―	22.29%	31.93%
PRPO	56 Neutral	$51.42M	-92.19	-10.07%	―	30.95%	59.67%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SERA	48 Neutral	$77.58M	-4.85	-47.69%	―	1.06%	22.41%
VNRX	47 Neutral	$25.76M	―	76.82%	―	14.48%	36.83%